FW: AUTO-IMMUNE Digest - 30 Oct 2003 to 31 Oct 2003 (#2003-111)

[Guest guest]

-----Original Message-----

From: IMSSF Auto-Immune Listserv

[mailto:AUTO-IMMUNE@...]On Behalf Of Automatic digest

processor

Sent: November 1, 2003 12:06 AM

Recipients of AUTO-IMMUNE digests

Subject: AUTO-IMMUNE Digest - 30 Oct 2003 to 31 Oct 2003 (#2003-111)

There is one message totalling 156 lines in this issue.

Topics of the day:

1. Clinical Effects of Copaxone (Glatiramer) or Interferon Therapy

Compared

to Untreated Patients with Relapsing-Remitting Multiple Sclerosis

----------------------------------------------------------------------

Date: Fri, 31 Oct 2003 08:15:00 -0500

From: Irwin Mortman <Irwin@...>

Subject: Clinical Effects of Copaxone (Glatiramer) or Interferon Therapy

Compared to Untreated Patients with Relapsing-Remitting Multiple Sclerosis

Posting of the following article has been=20

approved by The Doctor's Guide to the=20

Internet)(http://www.docguide.com)

Title: Clinical Effects of Copaxone (Glatiramer)=20

or Interferon Therapy Compared to Untreated=20

Patients with Relapsing-Remitting Multiple=20

Sclerosis

" Clinical Effects of Copaxone (Glatiramer) or=20

Interferon Therapy Compared to Untreated Patients=20

with Relapsing-Remitting Multiple Sclerosis "

Retrospective Observational Study and its Three=20

Year Extension Evaluated Relapse Rate,=20

Relapse-free and Disability Measures for all Four=20

Therapies KANSAS CITY, MO -- October 30, 2003 --=20

In a 16-month study published in the November=20

European Journal of Neurology, Copaxone=AE=20

(glatiramer acetate injection) was associated=20

with a significant reduction in relapse rate and=20

a high proportion of relapse-free patients=20

compared to an untreated group. The Argentinean=20

retrospective, observational study looked at 134=20

relapsing-remitting multiple sclerosis (RRMS)=20

patients comparing Copaxone or Interferon=20

treatment effects to a group of untreated=20

patients. A significant fall in the annual=20

relapse rate (compared with pretreatment values)=20

was observed for all four treatments and included=20

reductions of: Copaxone - 81 percent (n=3D30);=20

Rebif=AE - 66 percent (n=3D20); Betaseron=AE - 65=20

percent (n=3D20); Avonex=AE - 49 percent (n=3D26); no=20

treatment - 31 percent increase (n=3D38). The=20

percentages of relapse-free patients in each=20

group were: Copaxone - 83 percent; Avonex - 65=20

percent; Rebif - 60 percent; Betaseron - 60=20

percent; no treatment - 37 percent. =20

Carra, M.D., Department of Neurology, Hospital=20

Britanico de Buenos Aires, Argentina, spoke about=20

the results. " It is clear that immunomodulatory=20

therapy is beneficial in the long-term treatment=20

of relapsing-remitting patients compared to no=20

treatment. Our data are similar to those observed=20

in other studies published or presented. " (1-4)=20

The 16-month open-label study was extended for up=20

to three years. In a poster presented at the=20

European Committee for Treatment and Research in=20

Multiple Sclerosis (ECTRIMS) conference in Milan,=20

Italy, on the three year extension, the following=20

relapse rate reductions were observed: Copaxone=20

(glatiramer acetate injection) - 78 percent;=20

Rebif - 70 percent; Betaseron - 65 percent;=20

Avonex - 60 percent; no treatment - 31.5 percent=20

increase. Copaxone is indicated for the reduction=20

of the frequency of relapses in=20

relapsing-remitting MS. The most common side=20

effects of Copaxone are redness, pain, swelling,=20

itching, or a lump at the site of injection,=20

weakness, infection, pain, nausea, joint pain,=20

anxiety, and muscle stiffness. Copaxone is now=20

approved in 42 countries worldwide, including the=20

U.S., Canada, Australia, Israel, and all the=20

European countries. In Europe, Copaxone is=20

marketed by Teva Pharmaceutical Industries Ltd.,=20

and Aventis Pharma. In North America, Copaxone is=20

marketed by Teva Neuroscience, Inc. See=20

additional important information at=20

http://www.copaxone.com/pi/index.html or call=20

1-800-887-8100 for electronic releases. For=20

hardcopy releases, please see enclosed full=20

prescribing information. Copaxone=AE (glatiramer=20

acetate injection) is a registered trademark of=20

Teva Pharmaceutical Industries Ltd. References:=20

1. Panitch H, Goodin DS, Francis G, et al.=20

Randomized, comparative study of interferon beta=20

1a treatment regimens in MS: The EVIDENCE Trial.=20

Neurology 2002; 59: 1496-1506. 2. Durelli L,=20

Verdun E, Barbero P, et al. Independent=20

Comparison of Interferon (INCOMIN) Trial Study=20

Group. Lancet 2002 Apr. 27; 359 (9316): 1453-60.=20

3. Khan OA, et al. A prospective, open-label=20

treatment trial to compare the effect of IFNB-1a=20

(Avonex) IFNB-1b (Betaseron), and glatiramer=20

acetate (Copaxone) on the relapse rate in=20

relapsing- remitting multiple sclerosis. European=20

Journal of Neurology 2001; 8: 141-148. 4. Haas J=20

et al. Onset of Clinical Benefit of Copaxone in=20

Patients with Relapsing-Remitting Multiple=20

Sclerosis. Poster Presentation at the American=20

Academy of Neurology Annual Meeting 2003. SOURCE:=20

Teva Neuroscience, Inc.

Copyright =A9 2003 P\S\L Consulting Group Inc. All=20

rights reserved. Republication or redistribution=20

of P\S\L content is expressly prohibited without=20

the prior written consent of P\S\L. P\S\L shall=20

not be liable for any errors, omissions or delays=20

in this content or any other content on its=20

sites, newsletters or other publications, nor for=20

any decisions or actions taken in reliance on=20

such content.

--

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D

Searching the archives is available at:

http://PEACH.EASE.LSOFT.COM/archives/AUTO-IMMUNE.html

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D

To change your E-Mail address follow the steps below:

1. Remove yourself from the list using old E-Mail address

2. Subscribe to the list with new E-mail address

Instruction are provide below.

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D

If you ever want to remove yourself from this mailing list, send mail to:

LISTSERV@...

with the following command in the body of your email message:

" SIGNOFF AUTO-IMMUNE "

without the quotes

No text is required in the Subject area.

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D

To subscribe to the auto-immune list send an E-mail to

LISTSERV@...

In the body of the E-mail type

SUBscribe auto-immune " your name "

Without the quotes.

No text is required in the Subject area.

------------------------------

End of AUTO-IMMUNE Digest - 30 Oct 2003 to 31 Oct 2003 (#2003-111)

******************************************************************